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and heart failure: evidence from a bidirectional
Mendelian randomization study
Huachen Wang1†, Zheng Guo2†, Yulu Zheng2 and Bing Chen1*

Abstract
Background: Previous studies have observed inconsistent associations between coronavirus disease 2019 (COVID19) and heart failure (HF), but these studies were prone to bias based on reverse causality and residual confounding
factors. We aimed to investigate genetic liability between COVID-19 and heart failure using a bidirectional Mendelian
randomization study.
Methods: The causal relationship between COVID-19 (including COVID-19, hospitalized COVID-19 compared with
the general population, and severe COVID-19) and HF are determined by using a bidirectional Mendelian randomization analysis. We drew on summary statistics from the largest HF genome-wide association study (GWAS) metaanalysis on individuals of European ancestry, which included 47,309 HF patients and 930,014 controls. The inverse
variance weighted (IVW), an adaption of the Egger regression (MR-Egger), the weighted median, and weighted model
were conducted for the Mendelian randomization analysis to estimate a causal effect. To confirm the stability, we
performed a “leave-one-out” approach for the sensitivity analysis.
Results: Genetically predicted severe COVID-19 was not significantly associated with the risk of HF [odds ratio (OR),
1.003; 95% confidence interval (CI), 0.969–1.037; p = 0.867]. The IVW demonstrated that there was no association
between genetically hospitalized COVID-19 infection and HF risk [OR, 1.009; 95% CI, 0.939–1.085; p = 0.797]. There was
no evidence to support the association between genetically determined COVID-19 and the risk of HF [OR, 1.066; 95%
CI, 0.955–1.190; p = 0.253]. In addition, genetically predicted HF was also not causally associated with COVID-19 [OR,
1.162; 95% CI, 0.824–1.639; p = 0.393]. MR-Egger analysis indicated no evidence of directional pleiotropy.
Conclusion: The current bidirectional Mendelian randomization analysis overcomes the limitations of observational
studies. Our findings indicated that there is no causal association between COVID-19 and HF.
Keywords: COVID-19, Heart failure, Single nucleotide polymorphisms, Instrumental variable, Mendelian
randomization study
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Introduction
Coronavirus disease 2019 (COVID-19), caused by
severe acute respiratory syndrome coronavirus
type 2 (SARS-COV2), emerged in late 2019 and
rapidly developed into a global pandemic [1]. The
complications of COVID-19 infection appear to
be very broad, including acute respiratory distress
syndrome, secondary infection, cardiac injury such
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as heart failure (HF) [2, 3]. A considerable number of
case studies have shown that heart damage, such as
arrhythmia, cardiac arrest, and HF, are the end-stage
events of COVID-19 patients [4–6]. The mortality
rate of patients with heart injury is higher than that of
patients without heart injury [5–7]. Previous studies
have shown that the vast majority of acute heart
failure cases (77.9%) occurred in COVID-19-infected
patients with no history of heart failure [8]. Another
retrospective cohort study demonstrated that 52% of
HF patients infected with COVID-19 died and 12% of
the patients recovered and were discharged from the
hospital [9]. Some researchers have tried to detect the
possible association between COVID-19 infection and
HF [10, 11]. Cytokine storms, levels of ACE2, and the
levels of angiotensin II may be the causes of HF in the
COVID-19 infection population [5, 12–14]. Studies
based on endomyocardial biopsy and macrophages
showed that SARS-COV2 can reside within the heart
myocardial tissue; however, it does not prove that
SARS-COV2 plays a direct pathological role in HF
[15, 16]. Because of the inconsistent associations of
COVID-19 with HF, the causal relationship between
COVID-19 and HF infection needs to be further
explored.
Mendelian randomization (MR) has become an
analytic method that effectively probes genetic proxies
that are associated with exposures. Moreover, MR
plays a crucial role in separating true causal effects
from false associations caused by confounding effects
and reverse causal bias [17, 18]. If there is a causal
relationship between the exposures and the outcomes,
the genetic variation affecting the exposures will
also affect the outcomes. MR is considered a natural
simulation of a randomized controlled trial because
it is based on Mendel’s second law, which states that
alleles of different genes are independently assigned
to each other during gametogenesis. Thus, Mendelian
randomization analysis are based on the observation
that the inheritance of one trait should be independent
of the inheritance of other traits [19]. MR has also
been used in cardiovascular research, including
heart failure, to detect new underlying aetiological
mechanisms and to improve our understanding of the
current treatment methods [20, 21]. Therefore, we
performed bidirectional MR analysis for determining
the genetic variability in COVID-19 patients (including
COVID-19, hospitalized COVID-19 compared with
the general population and severe COVID-19) is
causally associated with HF. Understanding the
bidirectional relationship between COVID-19 and
HF is of significant public health importance about
complications management.
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Fig. 1 Three significant assumptions of COVID-19 on HF via forward
MR. Three different assumptions are represented by three paths.
Assumption 1: The SNPs are associated with COVID-19 (the exposure).
Assumption 2: The SNPs affect HF only through COVID-19 (exposure)
and not via any alternative causal pathways. Assumption 3: The SNPs
are completely independent from any potential confounding factors
that influence both COVID-19 and HF.

Fig. 2 Three significant assumptions of HF with COVID-19 via reverse
MR. Three different assumptions are represented by three paths.
Assumption 1: The SNPs are associated with HF (the exposure).
Assumption 2: The SNPs affect HF only through HF (exposure) and
not via any alternative causal pathways. Assumption 3: The SNPs are
completely independent from any potential confounding factors that
influence both COVID-19 and HF

Materials and methods
Study design

To ensure a valid MR analysis process, three significant assumptions need to be proven: (1) the SNPs are
associated with COVID-19 (HF), (2) the SNPs affect HF
(COVID-19) only through COVID-19 (HF) and not via
any alternative causal pathways, and (3) the SNPs are
completely independent from any potential confounding factors that influence both COVID-19 and HF
(Fig. 1, Fig. 2) [22, 23].
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Genetic association datasets for COVID‑19

Summary genetic association estimates for the risk
of COVID-19 were obtained from the release 5 of
COVID-19 GWAS published on January 18, 2021
(https://www.covid19hg.org/results/) [24]. We selected
three phenotypes from this GWAS: (1) patients with
COVID-19 relative to the general population including
38,984 patients and 1,644,784 control participants; (2)
hospitalized patients with COVID-19 compared with
the general population including 9986 patients and
1,877,672 control participants; and (3) patients with
very severe respiratory-confirmed COVID-19 compared
with the general population including 5,101 patients
and 1,383,241 control participants. All GWAS summary
statistics associated with COVID-19 were based on
populations of European ancestry excluding UK Biobank.
Genetic association datasets for heart failure

We determined the associations between the specific
SNPs and HF from the current largest GWAS metaanalysis of HF in populations of European descent [25].
The GWAS meta-analysis, which was conducted by the
Heart Failure Molecular Epidemiology for Therapeutic
Targets Consortium, included 26 studies (17 population
cohort studies, 38,780 HF cases, 893,657 controls and
nine case–control studies, 8,529 cases, 36,357 controls),
47,309 patients with heart failure, and 930,014 patients
as a control group [25]. This GWAS meta-analysis was
adjusted according to sex, age, and principal components.
In all of the cohort studies, heart failure was assessed
using at least one of the following methods: discharge
registration, cause of death registration, or physician
decision/diagnosis. Due to insufficient power, the GWAS
was not stratified according to the aetiological subtypes.
Genetic instrumental variables

From the GWAS summary data of COVID-19 patients,
we conducted a series of quality control steps to select
eligible instrumental SNPs. First, SNPs were chosen as
IVs for COVID-19 that were at the threshold from the
COVID-19 host genetics initiative. A few significant
SNPs of COVID-19 were available using the criterion
of p < 5 × 10^−8. SNPs that achieved significance
(p < 5 × 10^−8) for HF were selected as IVs. Second, we
only extracted the instrumental SNPs for the exposure
that were not in linkage disequilibrium ([LD], r2
threshold = 0.001). Among those pairs of SNPs, only the
SNP with the lowest P value was selected. In this study,
LD proxies were defined using European samples from
the 1000 Genomes Project. To test whether there was
a weak bias of the instrumental variable (i.e., genetic
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variation selected as an instrumental variable was weakly
correlated with exposure), we approximated that the F
statistic.

F statistic =

R2 × (N − 2)
(1 − R2)

R2 = 2 × eaf × (1 − eaf) × Beta2
N represents the sample size; eaf represents effect allele
frequency.
If the F statistic associated with instrument exposure
was much greater than 10, then the chance of a weak
instrument variable bias was small [26].
MR analysis

In the primary analysis of the MR analysis, we used the
standard inverse-variance weighted (IVW) method to
estimate the overall causal relationship between COVID19 and HF [27]. Using this method, the causal effect of the
exposure on the outcome was calculated from the ratio of
the SNP associated with the exposures (Wald estimate).
According to Mendel’s law of inheritance, MR assumes
that SNPs are randomly distributed in the general
population (separation, independent classification), and
this in turn simulates the process of randomization. SNPs
always appear before the development of the disease so a
reverse causality can be effectively eliminated.
MR is defined as a one-sample MR in a group with
complete SNP data, exposure, and results for all
participants [20]. Because of the difficulty in the statistics
in a single-sample MR, a two-sample MR was developed
to enable the analysis of two independent samples: one
for focusing on the exposures and the other to focus on
the outcomes [22]. In our study, we performed IVW,
which is an adaption of Egger regression (MR-Egger),
the weighted median approach and the weighted mode
approach. These four two-sample MR methods were
performed by the "TwoSampleMR" package in R (version
4.0.3) [28, 29]. The related analysis was all one-sided, and
evidence of a causal relationship was determined when a
prespecified p-value was lower than 0.05.
According to the superiorities of each MR, these four
methods can complement each other and provide a
more plausible causal relationship for our study. In a
two-sample MR analysis, we applied the IVW method to
analyze the associations between a genetically predicted
COVID-19 infection and HF. The MR-Egger method
was used to estimate confounding effects and to evaluate
directed pleiotropy with weaker assumptions. When 50%
or more of the genetic variations were valid instrumental
variables, the median-based method could give a reliable
effect estimate, which may be more suitable than the
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MR-Egger method. The weighting method provides
a more accurate causal estimation based on a weight
analysis. Compared with the traditional MR analysis,
the robust method estimates the causal effects that
consistently have weaker assumptions.
Traditional IVW methods are the appropriate method
to use summary data from a GWAS. We used it to
initially estimate the impact between COVID-19 and
HF [27]. First, we calculated the IVW average of SNPspecific associations with the fixed effects in HF. In
causal reasoning assumptions based on the MR analysis,
the analysis will give a biased estimate if one of the tools
is invalid [30]. Second, by selecting SNPs that predict
COVID-19, we addressed the first hypothesis (the
appropriate relationship between SNPs and COVID-19)
and the genetic variants that are significant factors for the
development of COVID-19 that might satisfy the second
hypothesis (without confounding factors). We used MR
Egger regression to study the directionality in order to
determine any possible violations of the third hypothesis.
Subsequently, we created a scatter plot to visually detect
the potential pleiotropy by showing the association
between each SNP and the risk of HF secondary to
COVID-19. The reverse analysis for the effect of HF on
COVID-19 is illustrated. A sensitivity analysis explained
the potential violations of the sufficient instrumental
variable assumption by using MR-Egger regression and
the weighted median. Our study also used the “leave-oneout” method for the sensitivity analysis. That is, when the
IVW method determined that there was a P value < 0.05
and, if the analysis passed the heterogeneity test and the
gene diversity test, each related SNP was then removed
one by one. The pooled effect of the remaining SNPs was
calculated to assess the impact of each SNP.

Results
To investigate the effect of genetic susceptibility to
COVID-19 on HF by utilizing bidirectional MR, we
employed independent SNPs that were associated with
COVID-19 as instrumental variables. The SNPs that
are associated with COVID-19 phenotypes and HF are
presented in Additional file 3: Table S1, S2, S3 and S4.
Causal effect of COVID‑19 on HF via forward MR

In the MR analysis, the estimated causal effect between
the COVID-19 phenotype and HF is shown in Table 1.
There was no genetical association of the severe COVID19 with HF using 9 SNPs presented in Table 1 (OR, 1.003;
95% CI, 0.969–1.037; p = 0.867), without directional pleiotropy (p = 0.664) and heterogeneity (p = 0.269). By using
the IVW method, the genetic predisposition of hospitalized COVID-19 patients compared with the general population was not observed to be statistically significantly
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Table 1 Causal association of COVID-19 with HF via MR analysis
Phenotype

Numbers OR (95% CI)
of SNPs

Beta (SE)

P

COVID-19 vs. population
IVW

5

1.066 (0.955–
1.190)

0.064 (0.056)

0.253

Weighted
median

5

1.036 (0.912–
1.176)

0.035 (0.065)

0.587

Weighted model 5

1.025 (0.855–
1.228)

0.024 (0.092)

0.806

MR-Egger

0.879 (0.680–
1.136)

− 0.129 (0.131) 0.398

5

egger_intercept

0.011

Q statistic

0.207
0.534

Hospitalized COVID-19 vs. population
IVW

5

1.009 (0.939–
1.085)

0.009 (0.037)

0.797

Weighted
median

5

1.015 (0.936–
1.101)

0.015 (0.041)

0.716

Weighted model 5

1.011 (0.893–
1.145)

0.011 (0.063)

0.868

MR-Egger

0.825 (0.665–
1.024)

− 0.192 (0.110) 0.180

5

egger_intercept

0.016

Q statistic

0.153
0.522

Severe COVID-19 vs. population
IVW

9

1.003 (0.969–
1.037)

0.003 (0.017)

Weighted
median

9

0.987 (0.944–
1.031)

− 0.013 (0.022) 0.562

Weighted model 9

0.979 (0.919–
1.041)

− 0.022 (0.032) 0.513

MR-Egger

0.976 (0.864–
1.103)

− 0.024 (0.062) 0.709

egger_intercept
Q statistic

9

0.014

0.867

0.664
0.269

HF Heart failure, CI Confidence interval, IVW Inverse-variance weighted; MR
Mendelian randomization, MR-Egger Egger regression, OR odds ratio, SE
Standard error, SNP Single-nucleotide polymorphism
Beta is the estimated effect size. P < 0.05 was considered statistically significant

associated with HF (OR, 1.009; 95% CI, 0.939–1.085;
p = 0.797). There was no association between the genetically instrumented COVID-19 and HF risk (OR, 1.066;
95% CI, 0.955–1.190; p = 0.253). The MR Egger intercept test further indicated no directional pleiotropy
(p = 0.207).
In the sensitivity analysis, we observed no consistent causal relationship between genetically predicted
COVID-19 phenotypes and HF using the "leave-oneout" approach, and this suggests that there is stability
in our results (Additional file 2: Figs. S1–S3). Figures 3,
4 and 5 presented the causal effect of the COVID-19
phenotypes on HF, in which the regression slopes of the
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Fig. 3 Scatter plot showing the associations of the SNP effects on COVID-19 against the SNP effects on HF. Circles indicate marginal genetic
associations with COVID-19 and risk of HF for each variant. Error bars indicate 95% CIs. COVID-19: Coronavirus disease 2019; HF: Heart failure; MR:
Mendelian randomization; SNP: Single nucleotide polymorphism

lines corresponded to the causal estimates using each
of the four different methods.(Additional file 1)
Causal association of HF with COVID‑19 via reverse MR

As shown in Table 2, the reverse MR analysis showed no
statistically significant evidence of a causal relationship
between HF and COVID-19 (OR, 1.162; 95% CI, 0.824–
1.639; p = 0.393), hospitalized COVID-19 compared
with the general population (OR, 1.173; 95% CI,
0.765–1.780; p = 0.464), and severe COVID-19 (OR,
0.539; 95% CI, 0.248–1.173; p = 0.119). The relationship
between the effect sizes of HF and the phenotypes of
COVID-19 are presented in Additional file 2: Figs. S4,
S5, and S6. There was no heterogeneity and directional
pleiotropy based on the Q test and MR-Egger intercept
test. The results of leave-one-out sensitivity analysis
showed that the association between genetically
instrumented HF with COVID-19 phenotypes were not
substantially driven by any individual SNP (Additional
file 2: Figs. S7–S9).

Discussion
To understand the causal relationship between COVID19 and HF, a bidirectional MR was performed on these
two groups using publicly summarized GWAS data.
Since genetic variants are substitutes for COVID-19,
some other studies have only shown that COVID19 is associated with HF [28, 29]; however, our study
showed no causal effect of COVID-19 genetic liability
on the HF risk. Furthermore, there was no MR evidence
indicating that genetic liability to HF increases the risk of
COVID-19.
Several retrospective studies have shown that HF is
the most common clinical manifestation of COVID19 after acute respiratory distress syndrome (ARDS),
respiratory failure, and sepsis [9, 31]. As a possible
serious consequence of myocardial injury associated
with COVID-19 [32, 33], HF is accompanied by high
mortality [13]. Meanwhile, decreased immune function
and general weakness in COVID-19 patients may be
risk factors for HF. It has been reported that monocytes
appear to produce more tumor necrosis factor alpha
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Fig. 4 Scatter plot showing the associations of the SNP effects on hospitalized COVID-19 compared with population against the SNP effects on
HF. Circles indicate marginal genetic associations with hospitalized COVID-19 and risk of HF for each variant. Error bars indicate 95% CIs. COVID-19:
Coronavirus disease 2019; HF: Heart failure; MR: Mendelian randomization; SNP: Single nucleotide polymorphism

(TNF-α) and interleukin-10 (IL-10) in COVID-19
patients [34]. TNF-α and IL-10 play different roles in
the inflammatory process. TNF-α is one of the most
important proinflammatory cytokines. It promotes
oxidative stress in areas of inflammation and indirectly
causes fever [35]. IL-10 plays a central role in infection by
limiting the immune response to pathogens [36].
Therefore, COVID-19 patients may be more prone to
myocardial damage and belong to the high-risk group for
HF. Although previous observational studies have shown
a correlation between COVID-19 and HF, the association
has not been established as to whether a genetic
susceptibility to COVID-19 plays a causal role in HF.
MR studies, an IV-based method to infer the causality
between intermediate phenotypes and disease, have been
widely conducted in HF research [26].
While a small number of cases directly develop viralassociated myocarditis and this may subsequently lead to
HF, in the majority of COVID-19 patients, heart muscle
damage or heart failure is due to mechanisms other
than natural viral infection alone [15, 32, 37–39]. To
date, few cases of COVID-19-related acute myocarditis

have been described in the literature. In some cases,
SARS-CoV-2 was present in macrophages but not in
cardiomyocytes. Furthermore, endomyocardial biopsies
have showed only low-grade interstitial myocardial
inflammation and specific changes in cardiac myocytes,
including myofibrillar lysis and lipid droplets [40].
These findings suggest that the virus can reside in the
heart, but these findings do not prove that the virus
has a direct pathogenic role in heart failure [15, 16]. A
recent study found that HF were not associated with the
risk of COVID-19 severity [41]. Our novel results first
indicated that the genetic liability of COVID-19 had no
causal effects on the risk of HF, which was consistent
with previous studies [15, 16]. These findings implied
that physicians should treat COVID-19 as a genuine
confounder and should pay more attention to the other
factors in high-risk individuals.
Our MR research has many advantages. First, we
performed four complementary MR methods to prevent
a reverse causal bias. Second, various SNPs were used
as a tool to study COVID-19, which made it possible to
detect the HF risk and provided a powerful genetic tool
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Fig. 5 Scatter plot showing the associations of the SNP effects on severe COVID-19 against the SNP effects on HF. Circles indicate marginal genetic
associations with severe COVID-19 and the risk of HF for each variant. Error bars indicate 95% CIs. COVID-19: Coronavirus disease 2019; HF: Heart
failure; MR: Mendelian randomization; SNP: Single nucleotide polymorphism

for COVID-19 infection. Third, the IVs used in our study
were independent SNPs that could minimize interference
from linkage disequilibrium.
There are also some limitations to our study. First, the
HF GWAS is from a pre-COVID-19 pandemic cohort.
This cohort does not have HF cases that are related to
COVID-19 infection and cannot capture the genetic
variants influencing the predisposition to COVID19-related HF. Future MR studies are needed when a
HF GWAS using post-COVID-19 cohort is available.
Second, a potential limitation of our study is that
some data may overlap across HF. Theoretically, ideal
data should be obtained from independent samples.
However, in practice, the initial GWAS studies mixed
some samples. Therefore, we used strong instruments
(i.e., F statistic much greater than 10) to minimize the
bias caused by overlapping [29]. Third, the genetic data
from the COVID-19 study focused on susceptibility and
severity. The susceptibility to and severity of COVID-19
were mixed in the original data. Our work requires more
specific clarification of the issue, but at present, we have
no methods to distinguish the two classifications. Fourth,

the small number of variants associated with COVID19 may have limited the statistical power in our study.
Fifth, although we used multiple methods to rule out
pleiotropy, the link between SNPs and COVID-19 may
still be through other means. We also cannot exclude
a common genetic basis between COVID-19 and HF.
These results were only derived from a statistical analysis,
so physicians must be more cautious about patients with
COVID-19. Thus, although our analysis did not provide
evidence of an association between genetic responsibility
for COVID-19 and HF, it does not exclude the value of
COVID-19 infection in HF risk prediction. In the future,
more research is needed to explore the association
between COVID-19 and HF from different perspectives.

Conclusions
This analysis used bidirectional MR to explore potential
causal associations between COVID-19 and HF.
Although there have been efforts to search for causal
mechanisms linking the two diseases, our analysis found
that COVID-19 is not causally associated with HF.
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Table 2 Causal association of HF with COVID-19 via reverse MR
analysis
Phenotype

Numbers OR (95% CI)
of SNPs

Beta (SE)

P

COVID-19 vs. population
IVW

4

1.162 (0.824–
1.639)

0.150 (0.176)

0.393

Weighted
median

4

1.240 (0.912–
1.686)

0.215 (0.157)

0.170

Weighted model 4

1.433 (0.850–
2.414)

0.360 (0.266)

0.270

MR-Egger

0.965 (0.302–
3.079)

− 0.036 (0.592) 0.957

4

egger_intercept

0.034

Q statistic

0.769
0.072

Hospitalized COVID-19 vs. population
IVW

4

1.173 (0.765–
1.780)

0.160 (0.218)

0.464

Weighted
median

4

1.373 (0.814–
2.318)

0.317 (0.267)

0.235

Weighted model 4

1.420 (0.648–
3.112)

0.350 (0.400)

0.446

MR-Egger

0.564 (0.191–
1.669)

− 0.572 (0.553) 0.410

4

egger_intercept

0.033

Q statistic

0.287
0.799

Severe COVID-19 vs. population
IVW

4

0.539 (0.248–
1.173)

− 0.618 (0.396) 0.119

Weighted
median

4

0.586 (0.225–
1.523)

− 0.535 (0.488) 0.273

Weighted model 4

0.592 (0.198–
1.770)

− 0.523 (0.559) 0.418

MR-Egger

0.655 (0.060–
7.136)

− 0.423 (1.218) 0.762

4

egger_intercept
Q statistic

0.066

0.881
0.859

HF Heart failure, CI Confidence interval, IVW Inverse-variance weighted, MR
Mendelian randomization, MR-Egger Egger regression, OR Odds ratio, SE
Standard error, SNP Single-nucleotide polymorphism
Beta is the estimated effect size. P < 0.05 was considered statistically significant

Abbreviations
COVID-19: Coronavirus disease 2019; HF: Heart failure; SNPs: Single nucleotide
polymorphisms; IVs: Instrumental variables; GWAS: Genome-wide association
studies; IVW: Inverse variance weighted; MR-Egger: An adaption of egger
regression; SARS-COV2: Severe acute respiratory syndrome coronavirus 2; MR:
Mendelian randomization; CIs: Confidence intervals; ORs: Odds ratios; ARDS:
Acute respiratory distress syndrome; TNF-α: Tumour necrosis factor α; IL-10:
Interleukin-10.
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